cerebral palsy with spasticity
Neurology · 2008–2025
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| incobotulinumtoxinA Treatment of moderate to severe spasticity of the upper limb and dynamic equinus foot deformity (lower limb spasticity) in patients with cerebral palsy aged 2… | Jul 2025 | Recommended with restriction | none received |
| botulinum toxin type A Treatment of moderate to severe spasticity of the upper limbs in children aged 2 years and over with cerebral palsy. | Nov 2008 | Recommended with restriction | no section in document |
What the PBS pays
$75M in government benefit over 2024–25, across 143,771 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| botulinum toxin type A | $72.8M |
| incobotulinumtoxinA | $2.6M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.